|
SPATS2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | <1E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.62447832963153E-12 |
| Normal-vs-Stage2 |
4.16749967868668E-11 |
| Normal-vs-Stage3 |
1.62481139653892E-12 |
| Normal-vs-Stage4 |
1.56390000949358E-09 |
| Stage1-vs-Stage2 |
4.993000E-01 |
| Stage1-vs-Stage3 |
3.232200E-01 |
| Stage1-vs-Stage4 |
8.930600E-01 |
| Stage2-vs-Stage3 |
1.801650E-01 |
| Stage2-vs-Stage4 |
6.861400E-01 |
| Stage3-vs-Stage4 |
4.220000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
1.0272999999561E-06 |
| Normal-vs-Asian |
2.44670950166892E-12 |
| Caucasian-vs-AfricanAmerican |
5.692200E-01 |
| Caucasian-vs-Asian |
6.497600E-01 |
| AfricanAmerican-vs-Asian |
4.021200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.62436730732907E-12 |
| Normal-vs-Female |
<1E-12 |
| Male-vs-Female |
4.979600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62436730732907E-12 |
| Normal-vs-Age(41-60Yrs) |
1.62436730732907E-12 |
| Normal-vs-Age(61-80Yrs) |
1.6251444634463E-12 |
| Normal-vs-Age(81-100Yrs) |
9.179700E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.349200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.087600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.769800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.303200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.681000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.948800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.264030E-01 |
| Classical-VS-Follicular |
5.828800E-01 |
| Classical-VS-Other |
9.314200E-01 |
| Classical-VS-Normal |
1.62447832963153E-12 |
| Tall-VS-Follicular |
2.586800E-01 |
| Tall-VS-Other |
3.432400E-01 |
| Tall-VS-Normal |
3.1616999995876E-07 |
| Follicular-VS-Other |
8.117800E-01 |
| Follicular-VS-Normal |
1.7027490528676E-12 |
| Other-VS-Normal |
4.117300E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.11022302462516E-16 |
| Normal-vs-N1 |
8.51119996703176E-09 |
| N0-vs-N1 |
5.166200E-02 |
|
|
